Results 131 to 139 of about 20,432 (139)
Some of the next articles are maybe not open access.

A Novel Polymorphism in ABCB1 Gene, CYP2B6*6 and Sex Predict Single-Dose Efavirenz Population Pharmacokinetics in Ugandans

British Journal of Clinical Pharmacology, 2009
Paul Waako   +2 more
exaly  

Pharmacokinetic Interactions Between Efavirenz and Rifampicin in HIV-Infected Patients With Tuberculosis

Clinical Pharmacokinetics, 2002
Jerónimo Pachón   +2 more
exaly  

Population Pharmacokinetics of Efavirenz in an Unselected Cohort of HIV-1-Infected Individuals

Clinical Pharmacokinetics, 2005
Jan M Prins   +2 more
exaly  

CYP2B6 (C.516G→T) And CYP2A6 (*9B And/Or *17) Polymorphisms Are Independent Predictors of Efavirenz Plasma Concentrations in HIV-Infected Patients

British Journal of Clinical Pharmacology, 2009
Awewura Kwara   +2 more
exaly  

Efficacy of 400 mg Efavirenz Versus Standard 600 mg Dose in HIV-Infected, Antiretroviral-Naive Adults (ENCORE1): A Randomised, Double-Blind, Placebo-Controlled, Non-Inferiority Trial

Lancet, The, 2014
exaly  

Efavirenz Plus Zidovudine and Lamivudine, Efavirenz Plus Indinavir, and Indinavir Plus Zidovudine and Lamivudine in the Treatment of HIV-1 Infection in Adults

New England Journal of Medicine, 1999
Karen T Tashima   +2 more
exaly  

Impact of Efavirenz Pharmacokinetics and Pharmacogenomics on Neuropsychological Performance in Older HIV-Infected Patients

Journal of Antimicrobial Chemotherapy, 2017
Susan Swindells   +2 more
exaly  

Unmasking Efavirenz Neurotoxicity: Time Matters to the Underlying Mechanisms

European Journal of Pharmaceutical Sciences, 2017
Nádia M Grilo   +2 more
exaly  

CYP2B6 Genotype Is a Strong Predictor of Systemic Exposure to Efavirenz in HIV-Infected Zimbabweans

European Journal of Clinical Pharmacology, 2012
Collen Masimirembwa   +2 more
exaly  
medicine
hiv
rifampicin
cyp2b6
tuberculosis
therapeutics
pharmacology
previous   12  13  14  

Home - About - Disclaimer - Privacy